Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.

NCT05441904 | Completed Phase 1

• 1 other identifier: PXL770-009
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

The study was planned in 2 parts: Parts A and B. In Part A, we tested 2 single doses of the study medicine in healthy volunteers: 500 mg and 750 mg. Part B was an optional part to test once-daily doses of the study medicine in healthy volunteers. We aimed to assess the safety, tolerability find out the side effects and blood levels of the PXL770.

Conditions

NASH - Nonalcoholic Steatohepatitis

Outcome Measures

Primary Outcomes (7)

• Cmax

  maximum concentration

  Blood samples for assay of PXL770 will be taken at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 and 144 hours after each dose.

• AUC

  area under the curve

  Blood samples for assay of PXL770 will be taken at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 and 144 hours after each dose.

• t1/2

  half-life

  Blood samples for assay of PXL770 will be taken at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 and 144 hours after each dose.

• tmax

  time to reach maximum concentration

  Blood samples for assay of PXL770 will be taken at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 and 144 hours after each dose.

• MRT

  mean residence time

  Blood samples for assay of PXL770 will be taken at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 and 144 hours after each dose.

• CL/F

  apparent clearance

  Blood samples for assay of PXL770 will be taken at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 and 144 hours after each dose.

• Vz/F

  volume of distribution

  Blood samples for assay of PXL770 will be taken at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 and 144 hours after each dose.

Secondary Outcomes (1)

• AE

  Safety monitoring will be done from the date of signature of the ICF until the end of the study, assessed up to 5 weeks.

Study Arms (1)

PXL770 500 and 750 mg

EXPERIMENTAL

Each subject received 1 dose of PXL770 at 500 mg and 1 dose at 750 mg

Drug: PXL770

Interventions

PXL770 DRUG

A single dose of 500 and 750 mg was administered to each subject.

PXL770 500 and 750 mg

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female healthy volunteer.
• Aged 18-55 years.
• A body mass index in the range 18.5-29.9.
• Body weight at least 50 kg.
• Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.
• Willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or their delegate.
• Agree to follow the contraception requirements of the trial.
• Agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication.
• Willingness to give written consent
• Registered with a General Practitioner in the UK.

You may not qualify if:

• Woman who is pregnant or lactating, or pre-menopausal woman who is sexually active and not using a reliable method of contraception.
• Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the volunteer.
• Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer's participation in the trial or make it unnecessarily hazardous.
• Estimated glomerular filtration rate at screening \< 90 mL/min/1.73 m2 (estimated using the method established by the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\]).
• Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness.
• Surgery (stomach bypass) or medical condition that might affect absorption of medicines.
• Presence or history of severe adverse reaction to any drug or a history of sensitivity to PXL770, or its excipients.
• Presence or history of anaphylactic or anaphylactoid reaction or food allergy.
• Use of a prescription medicine (except oral contraceptives or hormone replacement therapy in women), over-the-counter medicine with the exception of acetaminophen (paracetamol), dietary supplement or herbal remedy during the 14 days before the first dose of trial medication.
• Receipt of an investigational product (including prescription medicines) as part of another clinical trial within the 3 months before first admission to this study; in the follow-up period of another clinical trial at the time of screening for this study.
• Have previously taken PXL770 in another clinical trial.
• Presence or history of drug or alcohol abuse, or intake of more than 14 units of alcohol weekly, or more than 5 cigarettes, 1 cigar or pipe (about ¼ ounce tobacco) daily.
• Regular consumption of more than 5 cups of caffeinated drinks (or equivalent) daily.
• Blood pressure and heart rate in supine position at the screening examination outside the ranges: blood pressure 90-140 mm Hg systolic, 40-90 mm Hg diastolic; heart rate 40-100 beats/min. Borderline values (ie values that are within 5 mm Hg for blood pressure or 5 beats/min for heart rate) will be repeated in triplicate. Subjects can be included if the repeat value is within range or still borderline but deemed not clinically significant by the investigator.
• Vegetarians or vegans, or unwilling to eat up to two breakfasts including bacon.

Sponsors & Collaborators

• Poxel SA: lead

Study Sites (1)

HMR

London, NW10, 7EW, United Kingdom

Location

MeSH Terms

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo-5-phenyl-7H-thieno)(2,3-b)pyridin-4-olate potassium

Condition Hierarchy (Ancestors)

Fatty Liver; Liver Diseases; Digestive System Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 22, 2022
• First Posted: July 1, 2022
• Study Start: March 8, 2021
• Primary Completion: March 29, 2021
• Study Completion: March 29, 2021
• Last Updated: July 1, 2022

Record last verified: 2022-06

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)